Piramal Pharma Q2 net profit jumps over 4-fold to Rs 23 crore; revenue at Rs 2,242 crore

New Delhi: Piramal Pharma announced a consolidated net profit of Rs 23 crore for the second quarter ending in September, marking a more than four-fold increase. The Mumbai company had declared a profit of Rs 5 crore in the same quarter of the previous financial year. Piramal Pharma stated that revenue increased to Rs 2,242 crore in the second quarter from Rs 1,911 crore in the previous year.

Piramal Pharma Reports Strong Revenue Growth, Plans $80 Million Lexington Facility Expansion to Boost CDMO Busines.

"We are sustaining our trend of achieving strong revenue growth combined with year-over-year EBITDA margin increase." Piramal Pharma Chairperson Nandini Piramal noted that the main factor behind this growth has been the continuous expansion of our CDMO business, with an increase in innovative projects and revenue from patented products. She added that the company will invest $80 million in expanding the Lexington facility to meet the increasing demand for sterile fill-finish capabilities and continue the growth trend until the end of FY27. Piramal stated that they are observing consistent growth in volume in inhalation anesthesia products in the US and emerging markets in their CHG business.

ALSO READ: ৫ বছৰত আৰু ৫০টা বিমানবন্দৰ উন্নয়ন কৰাৰ লক্ষ্য চৰকাৰৰ: অসামৰিক বিমান পৰিবহণ মন্ত্ৰী

Expansion of capacity at Dahej (Gujarat) and Digwal (Telangana) is currently in progress to seize growth opportunities in the markets outside the Western region, she further mentioned. She also mentioned that the company is focusing on expanding its portfolio by creating a range of unique and specialized products to support sustainable growth in the long run. She mentioned that the company is still experiencing strong growth in power brands and e-commerce sales within the ICH (India consumer healthcare) business. Regarding the business sector, the company intends to expand its scope by shifting from a pharmacy-focused model to become a consumer healthcare company with an omnichannel approach. Piramal Pharma's shares were up by 11.74 pc trading at Rs 242.15 per share on the BSE.

ALSO READ: ACC Q2 FY25 नि फिथाय: मुलाम्फाया बोसोर बोसोराव 49 जौखोन्दो खमायनानै 200 कौटि रां जाबाय; खाजोनाया 4% बारायदों।